Vitamin D and multiple sclerosis: a comprehensive review
MB Sintzel, M Rametta, AT Reder - Neurology and therapy, 2018 - Springer
Numerous observational studies have suggested that there is a correlation between the
level of serum vitamin D and MS risk and disease activity. To explore this hypothesis, a …
level of serum vitamin D and MS risk and disease activity. To explore this hypothesis, a …
Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper)
Multiple sclerosis is a complex, autoimmune-mediated disease of the central nervous
system characterized by inflammatory demyelination and axonal/neuronal damage. The …
system characterized by inflammatory demyelination and axonal/neuronal damage. The …
ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis
Background: Multiple sclerosis (MS) is a complex disease with new drugs becoming
available in the past years. There is a need for a reference tool compiling current data to aid …
available in the past years. There is a need for a reference tool compiling current data to aid …
[HTML][HTML] Efficient multi-scale 3D CNN with fully connected CRF for accurate brain lesion segmentation
We propose a dual pathway, 11-layers deep, three-dimensional Convolutional Neural
Network for the challenging task of brain lesion segmentation. The devised architecture is …
Network for the challenging task of brain lesion segmentation. The devised architecture is …
MAGNIMS consensus recommendations on the use of brain and spinal cord atrophy measures in clinical practice
J Sastre-Garriga, D Pareto, M Battaglini… - Nature Reviews …, 2020 - nature.com
Early evaluation of treatment response and prediction of disease evolution are key issues in
the management of people with multiple sclerosis (MS). In the past 20 years, MRI has …
the management of people with multiple sclerosis (MS). In the past 20 years, MRI has …
Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial
Background The anti-CD52 monoclonal antibody alemtuzumab reduced disease activity in a
phase 2 trial of previously untreated patients with relapsing-remitting multiple sclerosis. We …
phase 2 trial of previously untreated patients with relapsing-remitting multiple sclerosis. We …
Multiple sclerosis: immunopathology and treatment update
N Dargahi, M Katsara, T Tselios, ME Androutsou… - Brain sciences, 2017 - mdpi.com
The treatment of multiple sclerosis (MS) has changed over the last 20 years. All
immunotherapeutic drugs target relapsing remitting MS (RRMS) and it still remains a …
immunotherapeutic drugs target relapsing remitting MS (RRMS) and it still remains a …
Vitamin D as an early predictor of multiple sclerosis activity and progression
Importance It remains unclear whether vitamin D insufficiency, which is common in
individuals with multiple sclerosis (MS), has an adverse effect on MS outcomes. Objectives …
individuals with multiple sclerosis (MS), has an adverse effect on MS outcomes. Objectives …
Classification, diagnosis, and differential diagnosis of multiple sclerosis
IK Sand - Current opinion in neurology, 2015 - journals.lww.com
Current multiple sclerosis phenotypic classifications include relapsing-remitting multiple
sclerosis, clinically isolated syndrome, radiologically isolated syndrome, primary …
sclerosis, clinically isolated syndrome, radiologically isolated syndrome, primary …
Safety and efficacy of rituximab versus dimethyl fumarate in patients with relapsing-remitting multiple sclerosis or clinically isolated syndrome in Sweden: a rater …
Background B-cell depleting therapies are highly efficacious in relapsing-remitting multiple
sclerosis but one such therapy, rituximab, is not approved for multiple sclerosis and no …
sclerosis but one such therapy, rituximab, is not approved for multiple sclerosis and no …